The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene label mismatch: PAH vs undefined
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000277.2(PAH):c.533A>G (p.Glu178Gly)

CA273110

92746 (ClinVar)

Gene: PAH
Condition: phenylketonuria
Inheritance Mode: Autosomal recessive inheritance
UUID: 9cbb36d6-2daf-4507-b947-3a692ec4d9e7
Approved on: 2025-04-18
Published on: 2025-04-18

HGVS expressions

NM_000277.2:c.533A>G
NM_000277.2(PAH):c.533A>G (p.Glu178Gly)
NC_000012.12:g.102855309T>C
CM000674.2:g.102855309T>C
NC_000012.11:g.103249087T>C
CM000674.1:g.103249087T>C
NC_000012.10:g.101773217T>C
NG_008690.1:g.67294A>G
NG_008690.2:g.108102A>G
ENST00000553106.6:c.533A>G
ENST00000307000.7:c.518A>G
ENST00000549111.5:n.629A>G
ENST00000551988.5:n.554A>G
ENST00000553106.5:c.533A>G
NM_000277.1:c.533A>G
NM_001354304.1:c.533A>G
NM_000277.3:c.533A>G
NM_001354304.2:c.533A>G
More

Pathogenic

Met criteria codes 5
PM3_Strong PS3_Supporting PP4_Moderate PP3_Moderate PM2_Supporting

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Phenylketonuria Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PAH Version 2.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Phenylketonuria VCEP
The c.533A>G variant in PAH is a missense variant predicted to cause substitution of glutamine by glycine at amino acid 178 (p.Glu178Gly). At least 5 patients with this variant displayed serum Phe levels > 6.5–10 mg/dl which is highly specific for PAH deficiency; BH4 deficiency was excluded (PP4_moderate, PMID: 18299955, PMID:9634518). Of those individuals, 4 probands were compound heterozygous for the variant and a pathogenic variant and 1 proband was compound heterozygous with a likely pathogenic variant (phase unknown, 2.25 points). The population allele frequency in gnomAD v4.1 is 0.00003965 which is lower than the ClinGen PAH VCEP threshold (<0.0002) for PM2_Supporting, meeting this criterion (PM2_Supporting). The results from in silico predictors [REVEL=0.841], predict a damaging effect on PAH function (PP3_moderate). Enzyme activity assay showed 39% residual phenylalanine hydroxylase activity indicating that this variant impacts protein function (PMID:17935162)(PS3_supporting). In summary, this variant meets criteria to be classified as pathogenic for PAH deficiency in an autosomal recessive manner based on the ACMG/AMP criteria applied, as specified by the ClinGen PAH Expert Panel: PM2_supporting, PP3_moderate, PS3_supporting, PP4_Moderate, PM3_Strong (version 2.0, 11/16/2024).
Met criteria codes
PM3_Strong
Detected with 3 pathogenic variants in 4 probands (0.5 points x 4 = 2.0 points) and 1 likely pathogenic variant (P281L) in 1 proband (0.25 points); phase unknown. 2.25 points
PS3_Supporting
39% residual phenylalanine hydroxylase activity
PP4_Moderate
Detected in at least 5 patients with serum Phe levels > 6.5–10 mg/dl. BH4 deficiency excluded. PMID: 18299955, PMID: 9634518
PP3_Moderate
REVEL=0.841
PM2_Supporting
Total AF 0.00003965 in gnomAD v4.1
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.